Ospemifene

DB04938ApprovedSmall moleculeEstrogen Agonist-antagonistsEstrogen Agonist/Antagonist

Ospemifene is a non-hormonal estrogen receptor modulator (SERM) used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

Chemical structure of Ospemifene
Mechanism
Curator reviewed
Primary indication
Ospemifene is indicated for the treatment of moderate to severe dyspareunia and vaginal dryness associated with menopause.Curator reviewed · 4 structured indications
Formula / weight
C24H23ClO2 · 378.891 g/mol (avg)
First approval
Canada, 2021 · United States, 2013 · European Union, 2020
Also known as
Deamino-hydroxytoremifene
Code names
FC-1271 · FC-1271A
Brand names
  • Osphena
  • Senshio

Resolves to

Compound
UNIIB0P231ILBKCAS128607-22-7ChEMBLCHEMBL2105395ChEBI73275PubChem3036505KEGGD08958
Clinical / RWD
RxNorm1370971ATCG03XC05
Structure
InChIKeyLUMKNAVTFCDUIE-VHXPQNKSSA-NSMILESOCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
Targets
P03372ESR1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
637Drug interactionsStructured to mechanism, not free text
Sign in
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
9ContraindicationsEach with its own population and attribute set
Sign in
11Marketed productsAcross 5 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 17 drug categories
Sign in
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ospemifene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In